0Studies tracked
0Claims cite
0Videos use
Average study score: 74/100
Bibliography
Studies by this author
1 study attributed to Matthew J. Armstrong on the platform. Click a card to read the full analysis.
Study
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
To investigate the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo in adults with biopsy-confirmed NASH-related compensated cirrhosis.